The U.S. generic drug supply is at a critical crossroad. With over 60% of generics made abroad, we face a fragile supply chain. This whitepaper analyzes how immediate tariffs to boost domestic manufacturing risk raising patient costs and disrupting access, and outlines the strategic, phased approach needed to secure our drug supply for the long term.

Unlock the secrets to extending survival in metastatic NSCLC: This study reveals how biomarker testing and targeted therapies are transforming patient outcomes in the real world.

Clinical trials are just the start. Discover how real-world data help life sciences companies implement market access strategies designed to get new drugs to patients who need them.

In today’s outcomes-driven healthcare landscape, real-world data (RWD) and real-world evidence (RWE) have emerged as critical tools to demonstrate clinical value, return on investment (ROI) and long-term impact beyond controlled trial environments.

Headache disorders including migraine are highly prevalent globally, estimated to affect more than 50% of the population at any point and time. In the U.S., migraine patients spend an average of $9,000 more than those without the diagnosis.

Unlock the Value of Effective Treatments: Discover how life sciences leaders can optimize patient outcomes and healthcare costs by addressing key questions about treatment adherence, healthcare utilization, and cost reduction.

An Antidote to Long-Standing Care and Cost Outcomes Analysis Frustrations Life Sciences Introduction In the ever-evolving landscape of healthcare, life sciences companies face a critical challenge: proving the real-world effectiveness and cost-efficiency of their therapies. ​ While clinical trials establish efficacy, understanding how treatments impact patient outcomes and healthcare costs in the real world remains…

The fact that healthcare organizations need to improve care outcomes is undeniably undisputed. To succeed, health plan leaders need to acknowledge that medical care is estimated to account for only 10% to 20% of the modifiable contributors to healthy outcomes for a population. The other 80% to 90% emanates from social determinants of health (SDOH),…

Introduction In today’s highly competitive healthcare marketing industry, marketers need to take a strategic approach to audience development that accounts for the intersection of factors that impact the provider’s ability to treat the patient, the marketer’s capacity to engage the attention of the healthcare provider, and the “knowability” of these factors. Drawing from the work…